Syros to Present on SY -1425, Its First-in-Class Selective RARα Agonist, in Oral Plenary Session at AACR Hematologic Malignancies Conference
Syros Announces FDA Acceptance of IND to Advance SY -1365, Its First-in-Class Selective CDK7 Inhibitor, into Phase 1 Clinical Trial in Patients with Advanced Solid Tumors
Syros Announces $35 Million Private Placement
TmaxSoft Drives Global Expansion with Nine Key Strategic Appointments in APAC and EMEA
Its slower cash burn is encouraging, but we remain concerned about end-market demand.
IRA experts weigh in on a tricky situation a client has with the IRS.